239 related articles for article (PubMed ID: 32859220)
21. Genetic profile of adult T-cell leukemia/lymphoma in Okinawa: Association with prognosis, ethnicity, and HTLV-1 strains.
Sakihama S; Morichika K; Saito R; Miyara M; Miyagi T; Hayashi M; Uchihara J; Tomoyose T; Ohshiro K; Nakayama S; Nakachi S; Morishima S; Sakai K; Nishio K; Masuzaki H; Fukushima T; Karube K
Cancer Sci; 2021 Mar; 112(3):1300-1309. PubMed ID: 33426772
[TBL] [Abstract][Full Text] [Related]
22. Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
Zhang Q; Lee B; Korecka M; Li G; Weyland C; Eck S; Gessain A; Arima N; Lessin SR; Shaw LM; Luger S; Kamoun M; Wasik MA
Leuk Res; 1999 Apr; 23(4):373-84. PubMed ID: 10229324
[TBL] [Abstract][Full Text] [Related]
23. Pathogenesis and treatment of human T-cell leukemia virus infection.
Ratner L
Immunol Res; 2005; 32(1-3):217-23. PubMed ID: 16106073
[TBL] [Abstract][Full Text] [Related]
24. Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia.
Imaizumi Y; Kohno T; Yamada Y; Ikeda S; Tanaka Y; Tomonaga M; Matsuyama T
Jpn J Cancer Res; 2001 Dec; 92(12):1284-92. PubMed ID: 11749693
[TBL] [Abstract][Full Text] [Related]
25. FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia.
Toulza F; Nosaka K; Takiguchi M; Pagliuca T; Mitsuya H; Tanaka Y; Taylor GP; Bangham CR
Int J Cancer; 2009 Nov; 125(10):2375-82. PubMed ID: 19544530
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression.
Wang L; Toomey NL; Diaz LA; Walker G; Ramos JC; Barber GN; Ning S
J Virol; 2011 Aug; 85(16):8328-37. PubMed ID: 21680528
[TBL] [Abstract][Full Text] [Related]
27. HTLV-1 and associated adult T-cell leukemia/lymphoma.
Mahieux R; Gessain A
Rev Clin Exp Hematol; 2003 Dec; 7(4):336-61. PubMed ID: 15129647
[TBL] [Abstract][Full Text] [Related]
28. The regulation of NDRG2 expression during ATLL development after HTLV-1 infection.
Ichikawa T; Nakahata S; Fujii M; Iha H; Shimoda K; Morishita K
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2633-2646. PubMed ID: 31295529
[TBL] [Abstract][Full Text] [Related]
29. Molecular insight into the study of adult T-cell leukemia/lymphoma (ATLL): Ten-year studies on HTLV-1 associated diseases in an endemic region.
Ashrafi F; Rahimzada M; Parandi M; Mirhosseini A; Mashkani B; Ahmadi Ghezeldasht S; Soltani A; Rafatpanah H; Mosavat A; Abdolrahim Rezaee S
Gene; 2022 Dec; 847():146885. PubMed ID: 36108787
[TBL] [Abstract][Full Text] [Related]
30. Targeting HTLV-1 activation of NFκB in mouse models and ATLL patients.
Rauch DA; Ratner L
Viruses; 2011 Jun; 3(6):886-900. PubMed ID: 21994759
[TBL] [Abstract][Full Text] [Related]
31. Cell signaling modifiers for molecular targeted therapy in ATLL.
Mori N
Front Biosci (Landmark Ed); 2009 Jan; 14(4):1479-89. PubMed ID: 19273141
[TBL] [Abstract][Full Text] [Related]
32. Adult T cell leukemia/lymphoma: FoxP3(+) cells and the cell-mediated immune response to HTLV-1.
Bangham CR; Toulza F
Adv Cancer Res; 2011; 111():163-82. PubMed ID: 21704832
[TBL] [Abstract][Full Text] [Related]
33. Importin β1 regulates cell growth and survival during adult T cell leukemia/lymphoma therapy.
Ishikawa C; Senba M; Mori N
Invest New Drugs; 2021 Apr; 39(2):317-329. PubMed ID: 32959166
[TBL] [Abstract][Full Text] [Related]
34. Clonal HTLV-I-infected CD4+ T-lymphocytes and non-clonal non-HTLV-I-infected giant cells in incipient ATLL with Hodgkin-like histologic features.
Ohshima K; Suzumiya J; Kato A; Tashiro K; Kikuchi M
Int J Cancer; 1997 Aug; 72(4):592-8. PubMed ID: 9259396
[TBL] [Abstract][Full Text] [Related]
35. Live attenuated VZV vaccination induces antitumor immunity in ATLL patients.
Jo T; Kubota-Koketsu R; Kaneko Y; Sakai T; Noguchi K; Irie S; Matsuo M; Taguchi J; Abe K; Shigematsu K
Cancer Immunol Immunother; 2023 Apr; 72(4):929-944. PubMed ID: 36181532
[TBL] [Abstract][Full Text] [Related]
36. Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma.
Arnulf B; Thorel M; Poirot Y; Tamouza R; Boulanger E; Jaccard A; Oksenhendler E; Hermine O; Pique C
Leukemia; 2004 Jan; 18(1):126-32. PubMed ID: 14574331
[TBL] [Abstract][Full Text] [Related]
37. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells.
Kohno T; Yamada Y; Akamatsu N; Kamihira S; Imaizumi Y; Tomonaga M; Matsuyama T
Cancer Sci; 2005 Aug; 96(8):527-33. PubMed ID: 16108835
[TBL] [Abstract][Full Text] [Related]
38. Experimental acute adult T cell leukemia-lymphoma is associated with thymic atrophy in human T cell leukemia virus type I infection.
Simpson RM; Zhao TM; Hubbard BS; Sawasdikosol S; Kindt TJ
Lab Invest; 1996 Mar; 74(3):696-710. PubMed ID: 8600320
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma.
Nadella MV; Dirksen WP; Nadella KS; Shu S; Cheng AS; Morgenstern JA; Richard V; Fernandez SA; Huang TH; Guttridge D; Rosol TJ
Leukemia; 2007 Aug; 21(8):1752-62. PubMed ID: 17554373
[TBL] [Abstract][Full Text] [Related]
40. Rigosertib is more potent than wortmannin and rapamycin against adult T-cell leukemia-lymphoma.
Ghorbanzadeh Neghab M; Jalili-Nik M; Soltani A; Afshari AR; Hassanian SM; Rafatpanah H; Rezaee SA; Sadeghnia HR; Ataei Azimi S; Mashkani B
Biofactors; 2023; 49(6):1174-1188. PubMed ID: 37345860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
